Does Medicaid cover Mounjaro in Pennsylvania?

If you’ve been prescribed a GLP-1 medication like Wegovy, Ozempic, or Mounjaro, you’ve probably asked yourself one crucial question: Will my insurance actually cover this? With list prices topping $1,000 per month, understanding your coverage options isn’t just helpful—it’s essential.

The short answer? It depends on your insurance type, your diagnosis, and whether you’re willing to navigate some paperwork. But don’t worry—this guide breaks down everything you need to know about insurance coverage for these breakthrough medications, including how to maximize your chances of approval and what to do if you’re denied.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into coverage details, let’s clarify what these medications are and why insurance companies treat them differently.

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition.

Ozempic (semaglutide) is FDA-approved for Type 2 diabetes management. While it’s the same active ingredient as Wegovy, insurers only cover it for its approved diabetes indication—not for weight loss alone.

Mounjaro (tirzepatide) is approved for Type 2 diabetes. Its sister medication, Zepbound (same drug, different branding), received FDA approval for obesity treatment.

This distinction matters enormously when it comes to insurance coverage. Most plans readily cover medications for diabetes management—it’s considered an essential health benefit. Weight-loss medications? That’s a different story entirely.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: What to Expect

Wegovy Coverage: Limited but Possible

If you have commercial health insurance through your employer or the ACA marketplace, Wegovy coverage is far from guaranteed. According to recent data, many employer-sponsored plans either exclude anti-obesity medications entirely or impose strict limitations due to cost concerns.

When coverage exists, expect rigorous requirements:

• BMI threshold: Most plans require BMI ≥30 (or ≥27 with qualifying comorbidities like hypertension, Type 2 diabetes, or sleep apnea)
• Documented lifestyle intervention: You’ll typically need proof of at least 6 months of supervised diet and exercise attempts
• Comorbidity documentation: Evidence of weight-related health conditions
• Step therapy: Some insurers require trying older, cheaper weight-loss medications first
• Age restrictions: Usually limited to adults 18 and older

Aetna’s clinical policy, for example, requires all of these criteria plus documentation that the patient isn’t using other weight-loss medications simultaneously. Even when approved, coverage is often granted for just 3-6 months initially, with continuation dependent on achieving at least 5% weight loss.

Ozempic and Mounjaro Coverage: Better for Diabetes

If you have Type 2 diabetes, you’re in a much better position. Most commercial plans cover both Ozempic and Mounjaro for their approved diabetes indication, typically placing them in Tier 3 (non-preferred brand) or Tier 4 (specialty).

Prior authorization is still common—insurers want to confirm your diabetes diagnosis and ensure you’ve tried first-line therapies like metformin unless there’s a clinical reason not to. But approval rates are significantly higher than for weight-loss indications.

Important note: Insurers actively prevent off-label use of diabetes medications for weight loss. If you’re prescribed Ozempic primarily for weight management and don’t have diabetes, expect a denial.

Medicare Coverage: Still Waiting

Here’s where things get frustrating for older adults. Federal law explicitly excludes Medicare Part D coverage of medications prescribed solely for weight loss. This restriction dates back to when Medicare was created and hasn’t caught up with modern medical understanding of obesity as a chronic disease.

The exception: Medicare does cover Wegovy when prescribed for cardiovascular risk reduction in patients with established heart disease and obesity—a new FDA indication approved in 2024. If you fit this specific profile, coverage is available, but you’ll need thorough documentation from your cardiologist.

For diabetes management, Medicare Part D covers both Ozempic and Mounjaro on most formularies, typically as higher-tier medications requiring prior authorization.

Some Medicare Advantage plans began offering limited obesity medication coverage in 2025, but benefits vary widely. Check your specific plan’s formulary if you have an MA plan rather than traditional Medicare.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage for GLP-1 weight-loss medications varies dramatically by state, and the landscape is shifting rapidly—mostly in the wrong direction for patients.

States That Cover Wegovy (With Restrictions)

As of late 2025, only about 13 states provide Medicaid coverage for anti-obesity medications, and that number is shrinking. States that do offer coverage invariably require prior authorization with strict criteria similar to commercial plans: high BMI, documented comorbidities, proof of lifestyle intervention attempts, and regular monitoring.

New York maintains coverage through its NYRx formulary, requiring PA but generally approving patients who meet BMI and comorbidity thresholds with proper documentation.

Pennsylvania added Wegovy coverage in 2023 with comprehensive PA requirements. However, the state announced it will discontinue coverage for weight-loss GLP-1s starting January 2026 due to budget constraints—a concerning trend.

States Without Coverage

Texas explicitly excludes all anti-obesity medications for Medicaid enrollees over age 21. The state exercised its option under federal law to not cover these drugs, citing cost considerations. Children under 21 may request case-by-case exceptions through EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) provisions.

Florida similarly does not cover weight-loss drugs on its Medicaid formulary, utilizing the federal optional exclusion.

Illinois hasn’t added obesity medications to its Medicaid program, despite expanding coverage for state employees.

California provided the most dramatic recent example of coverage rollback. After adding Wegovy to Medi-Cal in 2023, the state announced in December 2025 that coverage will end January 1, 2026, for all adults—a budget-driven decision affecting thousands of patients mid-treatment. Pediatric patients may still access coverage through EPSDT requirements.

This state-by-state variability creates significant health equity concerns, with low-income patients in non-coverage states having essentially no path to these medications without paying thousands of dollars out of pocket.

Prior Authorization: The Coverage Gatekeeper

Whether you have commercial insurance or live in a Medicaid-coverage state, prior authorization (PA) is virtually guaranteed for GLP-1 medications—especially for weight loss.

What Prior Authorization Requires

Your healthcare provider will need to submit documentation including:

• Current BMI calculation with height and weight
• Diagnosis codes for obesity and any comorbidities
• Detailed history of previous weight-loss attempts (diet programs, exercise regimens, behavioral counseling)
• Current medication list (to show you’re not on other weight-loss drugs)
• Justification for why this specific medication is medically necessary
• Treatment plan with goals and monitoring schedule

For diabetes indications, the PA focuses more on confirming diagnosis (A1c results, diagnosis codes) and documenting inadequate control on current therapy or contraindications to first-line medications.

Common Reasons for Denial

Understanding why PAs get denied helps you avoid these pitfalls:

1. Insufficient BMI documentation: Your recorded BMI falls below the threshold or wasn’t calculated recently enough
2. Missing lifestyle intervention proof: No documented evidence of the required 6-month diet and exercise program under medical supervision
3. Lack of comorbidity documentation: For BMI 27-29.9 patients, failing to clearly document qualifying health conditions
4. Step therapy not completed: Not trying required cheaper alternatives first
5. Plan exclusion: Your specific plan simply doesn’t cover anti-obesity medications, period
6. Off-label use: Requesting Ozempic for weight loss without a diabetes diagnosis

The Appeal Process

If your initial PA is denied, don’t give up. Appeal success rates are surprisingly good when clinical criteria are genuinely met but documentation was incomplete.

For your appeal, provide:

• A detailed letter of medical necessity from your provider explaining why this medication is essential for your health
• Additional documentation addressing whatever was missing in the initial submission
• Research or clinical guidelines supporting the treatment approach
• Documentation of health risks from continued obesity (labs, sleep study results, blood pressure logs, etc.)

Most insurers respond to initial PAs within 5-7 business days. Appeals may take 2-3 weeks. Some plans offer expedited appeals if delay creates health risks—work with your provider to request this if appropriate.

Pro tip: Platforms like Klarity Health can connect you with providers experienced in navigating insurance requirements for weight management, potentially improving approval odds through proper documentation from the start.

Understanding Medication Tiers and Costs

Even when covered, these medications aren’t cheap. Where your medication lands on your plan’s formulary tier structure determines your out-of-pocket costs.

Typical Tier Placement

• Tier 3 (Non-preferred brand): Common placement for Ozempic and sometimes Wegovy—expect 30-50% coinsurance or $40-100+ copays
• Tier 4 (Specialty): Where many plans place Wegovy and Mounjaro—often 25-33% coinsurance, potentially $200-400+ monthly
• Specialty tier: Some plans have a separate specialty tier with unique cost-sharing, particularly for medications requiring special handling

Prior Authorization Requirements by Medication

Self-Pay Options: New Programs Make It More Affordable

If insurance denies coverage or you don’t have insurance, you’re not completely out of luck. Recent pricing developments have significantly improved access.

GoodRx Partnership with Novo Nordisk

In November 2025, GoodRx launched a groundbreaking program in partnership with Novo Nordisk:

• Introductory pricing: $199 per month for your first two fills of Wegovy or Ozempic
• Ongoing pricing: Approximately $349 per month thereafter for most doses
• Availability: Works at nearly all major pharmacies nationwide
• No insurance needed: This is a true cash-pay program

This represents roughly a 60-70% discount from the typical $1,350 list price for Wegovy. The program includes access to a $39/month telemedicine subscription for weight management support.

Manufacturer Savings Programs

Novo Nordisk offers:

• Commercial insurance copay card: Can reduce copays to as low as $0 for insured patients (maximum $225 monthly savings)
• NovoCare Cash-Pay Program: $349/month self-pay price through their access program
• Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients based on income

Eli Lilly provides:

• Mounjaro savings card: $25 monthly copay for commercially insured diabetes patients
• Zepbound vials: Self-pay pricing from $299-$449 monthly (dose-dependent) through LillyDirect
• Patient assistance: Free medication programs for those meeting financial criteria

Important Limitations

Manufacturer copay cards cannot be used with government insurance (Medicare, Medicaid, TRICARE). They’re designed for commercially insured or cash-paying patients only.

Always verify current program details, as manufacturers adjust offerings based on market conditions and policy changes.

State-Specific Medicaid Coverage Details

Let’s dive deeper into what coverage looks like in key states:

California (Coverage Ending)

Current status (through 12/31/25): Medi-Cal covers Wegovy with PA requiring BMI ≥30 (or ≥27 with comorbidity) plus documented 6-month supervised diet. Quantity limited to 4 pens per 28 days.

Starting 1/1/26: All coverage ends for adults. This abrupt change leaves patients mid-treatment scrambling for alternatives. Pediatric patients may still access coverage through EPSDT provisions requiring medically necessary care for children.

Pennsylvania (Coverage Ending)

Currently covers Wegovy as a preferred agent with strict PA criteria: BMI ≥30 or ≥27 with comorbidity, documented weight-related health condition, and proof of lifestyle intervention. Patients with diabetes must try a diabetes-specific GLP-1 first.

Starting January 2026, PA Medicaid will cease covering GLP-1s for weight loss—another casualty of budget constraints.

New York (Still Covering)

The NYRx statewide formulary maintains Wegovy coverage with PA. Criteria mirror FDA labeling: appropriate BMI, comorbidities, and documented lifestyle modification. Approval rates appear reasonable for patients meeting requirements.

Texas and Florida (No Coverage)

These states exercise the federal option to exclude anti-obesity medications entirely for adult Medicaid enrollees. Only diabetes-indicated uses of GLP-1s receive coverage.

This creates a significant access gap for low-income patients in these large states.

Telehealth and Insurance: A Match Made in Heaven

One silver lining: if you’re pursuing GLP-1 treatment through telehealth, your insurance very likely covers the virtual visits themselves.

Telehealth Parity Laws

Over 40 states now have parity laws requiring private insurers to cover telehealth services equivalently to in-person care. Since the COVID-19 pandemic, both commercial insurance and Medicare significantly expanded telehealth coverage, and most changes became permanent.

What This Means for You

• Initial consultations: Covered at the same rate as office visits
• Follow-up appointments: Monitoring visits required by PA criteria can be done virtually
• Nutritional counseling: Obesity counseling is an ACA-mandated preventive service—covered even when done by telehealth
• Prescription management: Medication adjustments and monitoring can happen remotely

Important considerations:

• Use an in-network provider when possible to maximize coverage
• Most plans require live video (not just phone or text) for full coverage
• Some platforms operate on a cash-pay basis for the visit even if the prescription is then billed to insurance

Klarity Health, for example, provides accessible, transparent telehealth consultations with experienced providers who understand both the clinical aspects of weight management and the insurance landscape. With nationwide provider availability and clear pricing whether you’re using insurance or paying cash, you can get the care you need without surprise bills or endless phone trees.

Step Therapy Requirements: The Hoops You May Need to Jump Through

Many insurance plans implement step therapy protocols, requiring you to try certain treatments before approving more expensive options.

For Weight Loss (Wegovy)

Common step therapy might require:

1. Documented attempts at lifestyle modification (diet and exercise) for at least 6 months
2. Trial of older anti-obesity medications like:

• Phentermine (generic, ~$30/month)
• Orlistat/Alli (over-the-counter or prescription)
• Contrave (combination naltrexone/bupropion)

1. Only after inadequate response to these may Wegovy be approved

For Diabetes (Ozempic/Mounjaro)

Typical step therapy requires:

1. Trial of metformin (first-line diabetes medication) unless contraindicated
2. Addition of a second oral agent or GLP-1 if A1c remains elevated
3. Some plans require trying Ozempic before approving Mounjaro due to cost differences

Override Criteria

Step therapy can sometimes be bypassed if your provider documents:

• Contraindications to required first-line medications
• Previous intolerance or ineffectiveness of stepped medications
• Clinical urgency requiring the most effective treatment immediately

Comparing Your Options: Coverage at a Glance

What to Do If You’re Denied Coverage

Receiving a denial is frustrating but not necessarily the end of the road.

Immediate Steps

1. Request the denial letter: Get it in writing with specific reasons
2. Review your plan documents: Confirm whether anti-obesity medications are covered at all
3. Check for documentation gaps: Often denials result from incomplete submissions rather than ineligibility
4. Gather additional evidence: Work with your provider to address specific denial reasons

When to Appeal vs. When to Pursue Alternatives

Appeal if:

• You genuinely meet all clinical criteria but documentation was insufficient
• The denial cited lack of information you can provide
• The denial seems to misinterpret your clinical situation
• You have a unique medical circumstance that warrants exception

Consider alternatives if:

• Your plan explicitly excludes all weight-loss medications
• You’ve been denied multiple times despite meeting criteria
• Appeals are taking longer than you can wait for treatment
• Self-pay or manufacturer programs offer viable access

Finding Affordable Alternatives

If insurance won’t cover your preferred medication:

• Explore manufacturer patient assistance programs (free meds if you qualify)
• Check for clinical trials in your area recruiting participants
• Consider older, cheaper weight-loss medications as bridge therapy
• Use GoodRx or manufacturer cash-pay programs at new reduced prices
• Investigate whether you qualify for coverage through a different insurance product (spouse’s plan, ACA marketplace during open enrollment, etc.)

The Future of GLP-1 Coverage

The landscape is evolving rapidly, though not necessarily in patients’ favor.

Trends to Watch

Budget pressures: More states and employers are restricting coverage due to costs. California and Pennsylvania’s 2026 cuts signal a concerning trend that may spread.

Potential Medicare expansion: Federal legislation has been proposed to add obesity medication coverage to Medicare, though passage remains uncertain. The ‘Treat and Reduce Obesity Act’ has bipartisan support but faces cost concerns.

Manufacturer pricing: The late-2025 price reductions from Novo Nordisk and Eli Lilly suggest market pressure is finally working. Continued competition may drive prices down further.

Generic timeline: Patents on these medications extend into the 2030s, so true generics remain distant. However, biosimilar competition could emerge sooner in international markets.

Making Insurance Work for You

Successfully navigating GLP-1 insurance coverage requires patience, persistence, and good documentation. Here’s your action plan:

Before You Start

1. Check your formulary: Look up whether your medication is covered at all
2. Understand your plan’s requirements: Review PA criteria before your appointment
3. Document everything: Keep records of weight, health metrics, lifestyle interventions
4. Choose experienced providers: Work with clinicians familiar with insurance requirements

During the Process

1. Be thorough: Provide every piece of requested documentation upfront
2. Follow up regularly: Don’t assume silence means progress
3. Keep copies: Document all submissions and communications
4. Meet deadlines: Appeal windows are strict and missing them can mean starting over

If You Need Help

Klarity Health’s providers understand the insurance complexities around weight management medications. With transparent pricing (starting at $99 for consultations), quick appointment availability, and experience with both insurance-covered and cash-pay options, Klarity removes the barriers that often prevent people from accessing effective weight loss treatment. Whether your insurance covers GLP-1s or you’re considering self-pay options, you’ll get clear guidance from the start.

Your Questions Answered

Can I use my FSA or HSA to pay for GLP-1 medications?

Yes, when prescribed for a medical condition (obesity with BMI ≥30 or ≥27 with comorbidities, or diabetes), GLP-1 medications qualify as eligible medical expenses for Health Savings Accounts and Flexible Spending Accounts. This applies whether you’re paying with insurance copays or cash-pay. Keep receipts and your prescription documentation.

What if I lose weight and no longer meet BMI criteria?

Most insurance PAs for Wegovy require periodic reauthorization (every 3-6 months). If your BMI drops below the threshold and you no longer have qualifying comorbidities, coverage may be discontinued. Some providers argue for continued coverage to maintain weight loss, but insurers often reject this reasoning. Discuss transition plans with your provider before this becomes an issue.

Can I get Ozempic covered for weight loss if I have prediabetes?

Probably not. Prediabetes doesn’t qualify as Type 2 diabetes for insurance purposes. Most plans only cover Ozempic when A1c is ≥6.5% (diabetes range). If you’re close, your provider might order repeat testing, but trying to use diabetes medications off-label for prediabetes/weight loss typically results in denial. Wegovy would be the appropriate medication to request if you meet weight criteria.

Do I need to keep doing lifestyle interventions after starting medication?

Yes, for multiple reasons. First, these medications work best combined with healthy eating and activity. Second, insurance PAs often require ongoing documentation of lifestyle interventions for continued coverage. Third, when you eventually stop the medication, maintained lifestyle changes help prevent weight regain. Think of GLP-1s as a tool that works alongside—not instead of—healthy habits.

What happens if my state drops Medicaid coverage while I’m on treatment?

Unfortunately, you’ll need to transition off the medication or find alternative funding. Some options include manufacturer patient assistance programs (if you qualify by income), self-pay programs at reduced prices, or switching to an older, cheaper weight-loss medication your state still covers. Don’t stop abruptly—work with your provider to taper safely or transition to an alternative approach. Some advocacy groups are fighting these coverage cuts and may offer resources.

Take Action: Getting Started with GLP-1 Treatment

If you’re considering GLP-1 medication for weight loss or diabetes management, don’t let insurance concerns stop you from exploring your options.

Start by:

1. Reviewing your specific insurance plan’s formulary and PA requirements
2. Scheduling a consultation with a provider experienced in weight management
3. Gathering documentation of your weight history, health conditions, and previous treatments
4. Exploring both insurance-covered and self-pay options to understand your full range of choices

Remember, even if insurance coverage is uncertain, the landscape has improved significantly with new affordable self-pay options and manufacturer programs. The conversation with your healthcare provider is the critical first step.

Your health is worth the effort to navigate these systems, and the potential benefits of effective obesity treatment—improved metabolic health, reduced cardiovascular risk, better quality of life—make persistence worthwhile.

Key Takeaways

✓ Commercial insurance may cover Wegovy for obesity with strict PA criteria, but many plans exclude it entirely. Diabetes medications (Ozempic, Mounjaro) are more widely covered for their approved indications.

✓ Medicare doesn’t cover weight-loss drugs except in specific circumstances (cardiovascular indication), but does cover diabetes GLP-1s on Part D.

✓ Medicaid coverage varies dramatically by state and is shrinking—check your state’s specific formulary and prepare for possible changes.

✓ Prior authorization is virtually guaranteed and requires thorough documentation. Appeal denials when you genuinely meet criteria.

✓ Self-pay options have improved dramatically with GoodRx pricing at $199-349/month and manufacturer programs offering significant savings or free medication for qualifying patients.

✓ Telehealth visits for weight management are generally covered by insurance under parity laws, making access more convenient than ever.

✓ When insurance barriers seem insurmountable, experienced providers at platforms like Klarity Health can help navigate options, whether insurance-covered or cash-pay, with transparent pricing and quick availability.

📅 RESEARCH CURRENCY STATEMENT (Verified as of December 17, 2025)

This article incorporates the latest insurance formulary updates, pricing changes, and Medicaid policy shifts through December 2025. Coverage policies can change with new plan years—always verify details with your specific insurance provider.

Sources and References

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists (May 2024). Available at: www.aetna.com

2. California Department of Health Care Services – Medi-Cal GLP-1 Coverage Changes (December 2025). Available at: www.cmadocs.org

3. KFF Issue Brief – Medicaid Coverage of and Spending on GLP-1s (November 2024). Available at: www.kff.org

4. GoodRx Press Release – New $39 Weight Loss Telemedicine Subscription and Reduced Ozempic/Wegovy Pricing (November 17, 2025). Available at: www.businesswire.com

5. Fierce Pharma – Novo Nordisk and Lilly Lower Self-Pay Prices for GLP-1 Medications (November-December 2025). Available at: www.fiercepharma.com and www.fiercepharma.com

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499